Wave Life Sciences Ltd. (WVE)

Market Cap	368.50M
Revenue (ttm)	4.18M
Net Income (ttm)	-152.90M
Shares Out	86.91M
EPS (ttm)	-2.27
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	416,806
Open	4.18
Previous Close	4.18
Day's Range	3.99 - 4.31
52-Week Range	1.16 - 7.12
Beta	-0.87
Analysts	Buy
Price Target	8.16 (+92.45%)
Earnings Date	Mar 22, 2023

About WVE

Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional proteins, or modulate protein expression. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 11, 2015
• Employees: 235
• Stock Exchange: NASDAQ
• Ticker Symbol: WVE

Financial Performance

In 2021, WVE's revenue was $40.96 million, an increase of 104.03% compared to the previous year's $20.08 million. Losses were -$122.25 million, -18.45% less than in 2020.

Analyst Forecast

According to 11 analysts, the average rating for WVE stock is "Buy." The 12-month stock price forecast is $8.16, which is an increase of 92.45% from the latest price.

Price Target

$8.16

(92.45% upside)

Analyst Consensus: Buy